| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
iii
|
|
|
|
New treatments for multiply drug-resistant Gram-positive bacteria
|
Robert C. Moellering
|
S1-S3
|
|
|
|
Infections caused by Gram-positive bacteria: a review of the global challenge
Summary: Infections caused by multidrug-resistant Gram-positive bacteria represent a major public health burden, not just in terms of morbidity and mortality, but also in terms of increased expenditur...
|
Neil Woodford,
David M. Livermore
|
S4-S16
|
|
|
|
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria
Summary: Several new antimicrobials demonstrate in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and other Gram-positive bacteria. ...
|
George M. Eliopoulos
|
S17-S24
|
|
|
|
Treatment options for nosocomial pneumonia due to MRSA
Summary: Nosocomial pneumonia, which includes hospital-acquired pneumonia, ventilator-associated pneumonia, and health care associated pneumonia, remains an important cause of morbidity and mortality....
|
Michael S. Niederman
|
S25-S31
|
|
|
|
Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria
Summary: Gram-positive aerobes are the most common organisms in hospitalized patients with skin and soft-tissue infections (SSTIs). Staphylococcus aureus is the most common Gram-positive aerobe among ...
|
Dennis L. Stevens
|
S32-S39
|
|
|
|
Health economic issues in the treatment of drug-resistant serious Gram-positive infections
Summary: Escalating health care costs have stimulated a paradigm change in the way health care is delivered, reimbursed, and evaluated. Reducing the length of hospital stay and controlling the cost of...
|
Dilip Nathwani
|
S40-S50
|
|
|
|
Treatment of pediatric Gram-positive multidrug-resistant infections
Summary: Gram-positive organisms are the most common cause of bacterial infections in infants, children, and adolescents, accounting for 80% of community-acquired and 60% of hospital-acquired bacteria...
|
Jeffrey Blumer
|
S51-S58
|
|
|
|
Linezolid: a review of safety and tolerability
Summary: Linezolid has demonstrated activity against antibiotic-susceptible and antibiotic-resistant aerobic Gram-positive cocci. The availability of intravenous and oral formulations, with near 100% ...
|
Donald C. Vinh,
Ethan Rubinstein
|
S59-S74
|
|
|
|
Future gazing in the management of multiply drug-resistant Gram-positive infection
Summary: Gram-positive bacteria have evolved to become predominant health care associated pathogens. To meet this challenge, novel approaches to the development, prescribing, and control of antibiotic...
|
Mark H. Wilcox
|
S75-S80
|
|
